Regularly Scheduled Series Name

Course No. 22DXX

Friday, July 14, 2017

11:30am - 12:00pm

**\* \* \* Location and/or Virtual Link \* \* \***

**“Title of Talk”**

- - - - - - - - - - - - - - - - - - - -

Presented by:

**First Name Middle Initial/Name Last Name, Degree**

**(Title if applicable)**

**Professional Practice Gaps: {SAMPLE}** Practitioners (1) may not know that most preterm infants independently breathe at birth; (2) are often unable to support spontaneous breathing effectively, requiring babies to be intubated soon after birth; (3) may find it interesting to learn that failure to maintain self-ventilating from birth can be predicted by close observation of the baby’s oxygen requirement; (4) might be unaware of the benefits and pitfalls of the wide choice of interventions and devices available to support the newborn patient’s respirations.

**Learning Objectives:**  Upon completion of this session, participants will improve their competence and performance by being able to: **{SAMPLE}**

1. Identify the preterm infant with acute respiratory distress who would benefit from additional therapy.
2. Outline the underlying patho-mechanisms of respiratory distress at different time-points of disease progression.
3. Differentiate which mode of non-invasive ventilation to use in preterm infants with acute and ongoing lung disease.

**Accreditation Statement:** The University of Oklahoma College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Oklahoma College of Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit™.*  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ADD MOC STATEMENT IF APPLICABLE

ADD ADDITIONAL CREDIT STATEMENTS IF APPLICABLE

**Mitigation Statement:** The University of Oklahoma College of Medicine, Office of Continuing Professional Development has reviewed this activity’s speaker and planner disclosures and has mitigated all relevant financial relationships with ineligible companies, if applicable.

**Nondiscrimination Statement:** The University of Oklahoma, in compliance with all applicable federal and state laws and regulations, does not discriminate on the basis of race, color, national origin, sex, sexual orientation, genetic information, gender identity, gender expression, age, religion, disability, political beliefs, or status as a veteran in any of its policies, practices, or procedures. This includes, but is not limited to: admissions, employment, financial aid, housing, services in educational programs or activities, or health care services that the university operates or provides. Inquiries regarding non-discrimination policies may be directed to: Shaniqua Crawford, JD, Institutional Equity Officer and Title IX Coordinator, 405-325-3546, [scrawford@ou.edu](scrawford%40ou.edu), or visit <www.ou.edu/eoo.html>.

**Accommodation Statement:** For accommodations, please contact (Name) at (phone number and/or email).

**Disclaimer Statement:** Statements, opinions and results of studies contained in the program are those of the presenters and authors and do not reflect the policy or position of the Board of Regents of the University of Oklahoma (“OU”) nor does OU provide any warranty as to their accuracy or reliability.

Every reasonable effort has been made to faithfully reproduce the presentations and material as submitted. However, no responsibility is assumed by OU for any claims, injury and/or damage to persons or property from any cause, including negligence or otherwise, or from any use or operation of any methods, products, instruments or ideas contained in the material herein.

**Policy on Planner and Presenter Disclosure:** It is the policy of the University of Oklahoma College of Medicine that the faculty and presenters identify all financial relationships with ineligible companies relating to the topics of this educational activity, and also discloses discussions of off-label or investigational drugs/devices and/or therapies during their presentation(s).

**Acknowledgement of Commercial and In-Kind Support:** **Commercial support** is financial, or in-kind, contributions given by an ineligible company, which is used to pay all or part of the costs of a CME activity.  An ineligible company is any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

This activity is made possible by unrestricted educational grant(s) from (name(s) of ineligible companies).

**OR**

 This activity received no commercial or in-kind support.

**Disclosure & Mitigation Report**

The University of Oklahoma College of Medicine and the Irwin H. Brown Office of Continuing Professional Development must ensure balance, independence, objectivity and scientific rigor in all its accredited CE activities.  We have implemented a process where everyone who is in a position to control the content of an educational activity has identified to us all financial relationships with ineligible companies. In addition, should it be determined that a relevant financial relationship exists, this must be mitigated prior to the activity. This policy is designed to provide the target audience with an opportunity to review any affiliations between the CE planners and presenters and ineligible companies for the purpose of determining the potential presence of bias or influence over educational content. The following is a summary of this activity’s disclosure and mitigation information.

|  |  |
| --- | --- |
|  | **Nature of the Financial Relationship** |
| **Role(s)** | **First Name** | **Last Name** | **Ineligible Company** | **What Was Received** | **For What Role?** |
| **{SAMPLE}** Planning Member | James F. | Albertson, MA | I have no financial relationships or affiliations with ineligible companies to disclose. |
| **{SAMPLE}** Course Contact | Susie E. | Dealy, MEd | I have no financial relationships or affiliations with ineligible companies to disclose. |
| **{SAMPLE}** Planning Member/Moderator | Myrna R.  | Page, MPH, CHES | I have no financial relationships or affiliations with ineligible companies to disclose. |
| **{SAMPLE}** Course Director/Speaker | C.A. | Sivaram, MD | Medtronic | Honorarium | Consultant |
| **{SAMPLE} Planner:** Dr. Sivaram has recused himself from planning content in the conflicted area. **Speaker:** The conflict was resolved by Dr. Sivaram agreeing to not include discussion of products or services or make clinical recommendations on which the conflict exists. |